Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

Pluvicto, a drug to treat metastatic castration-resistant prostate cancer, also known as mCRPC, is in such short supply that its maker, Novartis, said it cannot allow further supply to new ...

New report finds colorectal cancer rising among U.S. adults under 55 04:17. Pluvicto, a drug used to treat advanced prostate cancer, is in short supply, the Food and Drug Administration reported ...

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) – formerly known as 177Lu-PSMA-617 – has been cleared in the US for previously-treated patients with PSMA-positive metastatic castration ...

FRANKFURT (Reuters) -Novartis said on Monday that its targeted radiotherapy Pluvicto was shown to slow progression of a certain type of prostate cancer, raising the prospect of treatment in an ...

Novartis Pluvicto prostate cancer radiotherapy. Novartis got a clinical data boost that could support its radiotherapy Pluvicto’s $2 billion-plus peak sales ambition.

The FDA approved Pluvicto, a Novartis radiopharmaceutical, as a new treatment option for advanced prostate cancer. Novartis added the therapy via its $2.1 billion acquisition of Endocyte four ...

“Personalizing treatment in this way may lessen harmful side effects, reduce damage to healthy cells and make it more likely ...

Pluvicto reduced the risk of radiographic progression or death by 59% in PSMA-positive mCRPC patients. In the Phase 3 PSMAfore trial, Pluvicto doubled median progression-free survival to 11.6 ...

He is a 10-year advanced prostate cancer survivor. ... It’s called Pluvicto. “Pluvicto is a radiation treatment, but not with a beam, it’s given with an IV into the body, ...

- Results highlight ATNM-400's potential as a transformative therapeutic option for prostate cancer patients with unmet clinical needs as expression of the target receptor for ATNM-400 persists ...